diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the second quarter ended June 30, 2014.
"We had a strong second quarter with 23 percent growth in our year-over-year revenue, including a significant contribution coming from our services agreement with GlaxoSmithKline (GSK) in addition to 7 percent growth in our base PLAC mass assay business,” said Lori Rafield, Ph.D., interim executive chair and chairman of the board for diaDexus.
